key: cord-0882938-fj9oxvb0 authors: Fisher, Matthew J.; Psevdos, George title: Asymptomatic SARS-CoV-2 Infection Following First Dose mRNA-1273 COVID-19 Vaccine in a Veterans Affairs Long Term Care Facility date: 2021-06-25 journal: Am J Infect Control DOI: 10.1016/j.ajic.2021.06.010 sha: 6bbbefede6fff980cb22a653253bc42d3f8fc0dc doc_id: 882938 cord_uid: fj9oxvb0 An outbreak of SARS-CoV-2 involving four residents of a U.S. Veterans Affairs long term care facility occurred following administration of the first dose of the mRNA-1273 vaccine (Moderna) to thirty out of thirty-three residents. Three out of four positive cases were partially vaccinated and remained asymptomatic. One of two partially vaccinated patients who were tested for anti-spike protein antibodies had detectable levels at the time of diagnosis. The mortality rate was lower compared to a prior outbreak reported in this facility. The authors have no competing interests to declare. In December 2020 the United States Centers for Disease Control recommended that healthcare workers and residents of long term care facilities (LTCFs) be prioritized to receive the first vaccines approved for coronavirus disease 2019 (COVID-19) during the initial phase of the COVID-19 vaccination program. [1] At the Northport Veterans Affairs Medical Center in New York, vaccination of residents No mutations associated with so-called variants of concern known to confer greater transmissibility or immune escape such as N501Y or E484K were discovered. [2] There were no other cases of COVID-19 identified among the remaining 27 patients who received the first dose of mRNA-1273, including 21 partially vaccinated residents with no prior history of COVID-19 infection ( Table 1 ). The fact that two of the positive patients' nucleocapsid antibodies were negative confirms that they were among those not previously infected. Of the three unvaccinated patients, two patients who previously recovered from symptomatic COVID-19 tested negative during this investigation, while the one patient in this facility who had neither previously been infected nor vaccinated for COVID-19 became the fourth positive case on January 22, and reported mild symptoms. There were no deaths as a result of this outbreak. In this small sample size, vaccine effectiveness after a single dose of mRNA-1273 was 70 percent. While both phase 3 clinical trials of mRNA vaccines demonstrated over 90 percent efficacy in preventing symptomatic COVID-19 after completing a two dose series, further studies have suggested that beginning two weeks after the first dose vaccine efficacy may already exceed 80 percent. [3, 4, 5] Opponents of delaying the second dose raise concerns about lower antibody titers particularly among older individuals following the first dose, and the potential for immune escape by variants of concern. [6] Residents of LTC facilities have been particularly vulnerable to the devastation of COVID-19, accounting for more than a third of all COVID-19 related deaths in the United States. [7] During a previous outbreak in associated LTCFs including this facility in March 2020, there were 25 cases identified with a case fatality rate of 26%. [8] It is encouraging that among these three patients at high risk for severe disease and mortality who received even a single vaccination, all remained asymptomatic, and the outbreak was limited to just four patients in total. We speculate that in addition to ongoing infection control measures, vaccination of residents of this facility with the first dose of mRNA-1273 may have mitigated both the extent of the outbreak and the severity of illness in those few who were ultimately infected. The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine -United States Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination COVID-19 Nursing Home Data. Submitted data as of week ending Halting a SARS-CoV-2 outbreak in a US Veterans Affairs nursing home Table 1. Positive SARS-CoV-2 Cases During The authors have no competing interests to declare.